Medicus Pharma’s (MDCX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report released on Monday,Benzinga reports. D. Boral Capital currently has a $9.00 target price on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, April 10th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Medicus Pharma currently has a consensus rating of “Hold” and an average price target of $14.50.

Medicus Pharma Stock Down 2.1%

Shares of NASDAQ MDCX opened at $0.34 on Monday. Medicus Pharma has a fifty-two week low of $0.29 and a fifty-two week high of $8.94. The business has a 50 day moving average price of $0.71 and a two-hundred day moving average price of $1.47. The firm has a market cap of $13.54 million, a PE ratio of -0.12 and a beta of 1.16.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50). On average, analysts anticipate that Medicus Pharma will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Armistice Capital LLC acquired a new position in shares of Medicus Pharma in the 4th quarter worth approximately $2,771,000. Jane Street Group LLC acquired a new position in shares of Medicus Pharma in the 4th quarter worth approximately $92,000. HRT Financial LP acquired a new position in shares of Medicus Pharma in the 4th quarter worth approximately $42,000. Commonwealth Equity Services LLC grew its position in shares of Medicus Pharma by 161.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB grew its position in shares of Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after acquiring an additional 25,622 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.